Previous Article | Next Article ![]()
Antimicrobial Agents and Chemotherapy, August 2001, p. 2229-2237, Vol. 45, No. 8
Centre de Recherche en Infectiologie,
Université Laval, Québec, QC, Canada
Received 27 November 2000/Returned for modification 8 March
2001/Accepted 18 May 2001
The microbicidal activity of sodium lauryl sulfate (SLS) against
human immunodeficiency virus type 1 (HIV-1) was studied in cultured
cells. Pretreatment of HIV-1NL4-3 with SLS decreased, in a
concentration-dependent manner, its infectivity when using 1G5 as
target cells. In the absence of a viral pretreatment period or when 1G5
cells were pretreated with SLS, the surfactant-induced inactivation of
viral infectivity was less pronounced, especially at concentrations
between 375 and 550 µM. SLS had no effect on HIV-1 when the virus was
adsorbed to 1G5 cells by a 2-h incubation period. SLS almost completely
inhibited the fusion process by decreasing the attachment of HIV-1 to
target cells. SLS also inhibited the infectivity of HIV-1-based
luciferase reporter viruses pseudotyped with the amphotropic murine
leukemia virus envelope (which enters cells in a CD4-, CCR5-, and
CXCR4-independent manner), indicating that SLS may inactivate other
envelope viruses. In contrast, no effect was seen with vesicular
stomatitis virus envelope glycoprotein G (which enters cells through
receptor-mediated endocytosis) pretreated with up to 700 µM SLS. SLS
also decreased, in a dose-dependent manner, the HIV-1-dependent
syncytium formation between 1G5 and J1.1 cells after a 24-h incubation.
The reduction of luciferase activity was more pronounced when J1.1
cells (which express HIV-1 proteins on their surface) were pretreated
with SLS rather than 1G5 cells. Taken together, our results suggest
that SLS could represent a candidate of choice for use in vaginal
microbicides to prevent the sexual transmission of HIV and possibly
other pathogens causing sexually transmitted diseases.
0066-4804/01/$04.00+0 DOI: 10.1128/AAC.45.8.2229-2237.2001
Copyright © 2001, American Society for Microbiology. All rights reserved.
Sodium Lauryl Sulfate Abrogates Human
Immunodeficiency Virus Infectivity by Affecting Viral
Attachment
*
Corresponding author. Mailing address: Centre de
Recherche en Infectiologie, Centre Hospitalier Universitaire de
Québec, Pavillon CHUL, 2705 Blvd. Laurier, Québec, QC,
Canada GIV 4G2. Phone: (418) 654-2705. Fax: (418) 654-2715. E-mail:
Michel.G.Bergeron{at}crchul.ulaval.ca.
This article has been cited by other articles:
| Clin. Vaccine Immunol. | Clin. Microbiol. Rev. |
|---|---|
| J. Clin. Microbiol. | ALL ASM JOURNALS |